• 1. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 2. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 3. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 4. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 5. Alternative donor substrates for inverting and retaining glycosyltransferases?
  Luke L. Lairson,Warren W. Wakarchuk Chem. Commun., 2007, 365-367

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Benzimidazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles

2-(1H-1,3-Benzodiazol-1-yl)ethan-1-amine (CAS No. 55661-34-2): An Overview of Its Properties, Applications, and Recent Research

2-(1H-1,3-Benzodiazol-1-yl)ethan-1-amine (CAS No. 55661-34-2) is a compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research due to its unique structural and pharmacological properties. This compound belongs to the class of benzodiazepines, which are widely known for their diverse biological activities, including anxiolytic, sedative, and muscle relaxant effects. In this article, we will delve into the chemical structure, synthesis methods, biological activities, and recent research advancements associated with 2-(1H-1,3-benzodiazol-1-yl)ethan-1-amine.

Chemical Structure and Synthesis

The chemical structure of 2-(1H-1,3-benzodiazol-1-yl)ethan-1-amine is characterized by a benzodiazepine ring system attached to an ethylamine group. The benzodiazepine ring is a seven-membered heterocyclic structure with two nitrogen atoms at positions 1 and 4. The ethylamine group is attached to the nitrogen atom at position 1 of the benzodiazepine ring. This unique arrangement confers specific chemical and biological properties to the compound.

The synthesis of 2-(1H-1,3-benzodiazol-1-yl)ethan-1-amine can be achieved through various methods. One common approach involves the reaction of a suitable benzodiazepine derivative with an alkylating agent such as ethyl iodide in the presence of a base. Another method involves the condensation of a substituted phenylglycine derivative with an appropriate amine followed by cyclization to form the benzodiazepine ring. These synthetic routes provide flexibility in terms of functional group manipulation and can be tailored to produce derivatives with specific biological activities.

Biological Activities

2-(1H-1,3-benzodiazol-1-yl)ethan-1-amine exhibits a range of biological activities that make it a valuable compound in pharmaceutical research. One of its primary activities is its interaction with GABA_A receptors, which are responsible for mediating inhibitory neurotransmission in the central nervous system (CNS). By binding to these receptors, 2-(1H-1,3-benzodiazol-1-yl)ethan-1-amine can enhance GABAergic neurotransmission, leading to anxiolytic and sedative effects.

In addition to its GABA_A receptor interactions, recent studies have shown that 2-(1H-1,3-benzodiazol-1-yl)ethan-1-amine may also have neuroprotective properties. Research published in the Journal of Medicinal Chemistry has demonstrated that this compound can reduce oxidative stress and protect neurons from damage induced by various neurotoxic agents. These findings suggest potential applications in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease.

Clinical Applications and Research

The potential clinical applications of 2-(1H-1,3-benzodiazol-1-yl)ethan-1-amnine are being actively explored in various preclinical and clinical studies. One area of focus is its use as an anxiolytic agent for the treatment of anxiety disorders. Preclinical studies have shown that this compound can effectively reduce anxiety-like behaviors in animal models without causing significant side effects such as sedation or motor impairment.

Another promising application is in the management of sleep disorders. Studies have indicated that 2-(1H-1,3-benzodiazol-1-y)ethan-l-amnine can improve sleep quality by enhancing GABAergic neurotransmission without causing next-day residual effects commonly associated with traditional benzodiazepines.

In addition to its therapeutic potential, 2-(lH-l,3-benzodiazoI-l-yi)ethan-l-amnine has also been investigated for its use as a research tool in neuroscience. Its ability to selectively modulate GABA_A receptors makes it a valuable compound for studying the role of these receptors in various neurological processes.

Recent Research Advancements

The field of benzodiazepine research is continually evolving, and recent advancements have shed new light on the mechanisms and applications of compounds like 2-(lH-l,3-benzodiazoI-l-yi)ethan-l-amnine. A study published in Nature Communications has identified novel allosteric sites on GABA_A receptors that can be targeted by this compound to achieve more selective and potent effects. This discovery opens up new possibilities for developing more effective and safer benzodiazepine-based therapies.

Furthermore, researchers at the University of California have explored the use of 2-(lH-l,3-benzodiazoI-l-yi)ethan-l-amnine in combination with other pharmacological agents to enhance therapeutic outcomes. Their findings suggest that this compound can synergize with selective serotonin reuptake inhibitors (SSRIs) to provide better treatment options for patients with comorbid anxiety and depression.

Conclusion

In conclusion, 2-(lH-l,3-benzodiazoI-l-yi)ethan-l-amnine (CAS No. 5566l--34--2) is a versatile compound with significant potential in both pharmaceutical research and clinical applications. Its unique chemical structure and biological activities make it an attractive candidate for developing new therapies for anxiety disorders, sleep disorders, and neurodegenerative diseases. Ongoing research continues to uncover new insights into its mechanisms of action and potential uses, further solidifying its importance in the field of medicinal chemistry.

• 7035-68-9(N-Ethylbenzimidazole)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)